PFS
VIR icon

Prospera Financial Services’s Vir Biotechnology VIR Stock Holding History

Prospera Financial Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-294
Closed -$8K – 2582
2022
Q1 		$8K Buy
+294
New +$8.72K ﹤0.01% 2142

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Prospera Financial Services's VIR Position: Q2 2022 in Review

Prospera Financial Services sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 294 shares — an estimated $8K sold.

Prospera Financial Services first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Prospera Financial Services reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 294 Vir Biotechnology shares in Q2 2022, an estimated $8K.
  • Prospera Financial Services first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Vir Biotechnology position peaked at $8K in Q1 2022.
  • 212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.